XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Up 27.4% in January

XOMA Royalty Corporation (NASDAQ:XOMA) saw a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 1,051,282 shares, a growth of 27.4% from the January 15th total of 824,924 shares. Currently, 9.1% of the company’s shares are short sold. Based on an average trading volume of 783,079 shares, the days-to-cover ratio is presently 1.3 days. Based on an average trading volume of 783,079 shares, the days-to-cover ratio is presently 1.3 days. Currently, 9.1% of the company’s shares are short sold.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th. Benchmark reissued a “buy” rating on shares of XOMA Royalty in a report on Friday, December 12th. Stifel Nicolaus set a $50.00 price objective on shares of XOMA Royalty in a research report on Friday, December 12th. Leerink Partners dropped their target price on shares of XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating for the company in a report on Thursday, December 11th. Finally, UBS Group set a $76.00 target price on XOMA Royalty in a research note on Tuesday, December 9th. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.60.

Insider Transactions at XOMA Royalty

In related news, CEO Owen Hughes purchased 100,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The shares were acquired at an average cost of $25.05 per share, with a total value of $2,505,000.00. Following the purchase, the chief executive officer directly owned 102,000 shares of the company’s stock, valued at approximately $2,555,100. This trade represents a 5,000.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 7.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in XOMA. Vanguard Group Inc. raised its position in shares of XOMA Royalty by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock worth $25,749,000 after acquiring an additional 29,298 shares in the last quarter. Opaleye Management Inc. grew its stake in XOMA Royalty by 0.8% in the second quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company’s stock worth $6,428,000 after purchasing an additional 2,044 shares during the period. Geode Capital Management LLC raised its holdings in XOMA Royalty by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 221,566 shares of the biotechnology company’s stock worth $5,893,000 after purchasing an additional 9,589 shares in the last quarter. Woodline Partners LP raised its holdings in XOMA Royalty by 16.5% in the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock worth $8,091,000 after purchasing an additional 29,715 shares in the last quarter. Finally, State Street Corp lifted its position in XOMA Royalty by 4.7% during the fourth quarter. State Street Corp now owns 174,908 shares of the biotechnology company’s stock valued at $4,651,000 after buying an additional 7,873 shares during the period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Royalty Trading Up 1.9%

NASDAQ:XOMA opened at $24.01 on Monday. The company has a 50-day moving average price of $26.44 and a 200-day moving average price of $31.15. The stock has a market cap of $297.24 million, a price-to-earnings ratio of 32.45 and a beta of 0.86. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $39.92.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.